Amgen says Imdelltra combo cut death risk 58% in first-line lung cancer

what happened

Amgen said that combining its drug Imdelltra with Imfinzi reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer receiving first-line treatment. According to the company, nearly 80% of patients on the combination were alive at one year, compared with 53% of those given durvalumab alone. Progression-free survival more than tripled.

Grade 3 or higher adverse events occurred in 20.9% of patients on the combination versus 10.8% on Imfinzi alone. Median overall survival reached 21.1 months, against 12.7 months with durvalumab alone. Amgen said the safety profile of the combination is consistent with the known profiles of the individual medicines.

why it matters

For Amgen shares, this is a strong clinical signal in oncology, but the figures come from the company itself and have not been independently assessed in this report. Investors are likely to weigh the rise in serious side effects, from 10.8% to 20.9%, when judging the drug's commercial potential.

market impact

Amgen: strong oncology data may support interest in Imdelltra and the company's shares

tags

instruments